📣 VC round data is live. Check it out!

Ypsomed Valuation Multiples

Discover Ypsomed's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Sysmex, Teleflex, Abbott India, Getinge and more.

Ypsomed Overview

About Ypsomed

Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.


Founded

2003

HQ

Switzerland

Employees

2.8K

Financials (LTM)

Revenue: $924M
EBITDA: $409M

EV

$6B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ypsomed Financials

Ypsomed reported last 12-month revenue of $924M and EBITDA of $409M.

In the same LTM period, Ypsomed generated $403M in gross profit, $409M in EBITDA, and $273M in net income.

Revenue (LTM)


Ypsomed P&L

In the most recent fiscal year, Ypsomed reported revenue of $930M and EBITDA of $415M.

Ypsomed is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 45%, and net margin of 30%.

See analyst estimates for Ypsomed
LTMLast FY202320242025202620272028
Revenue$924M$930M$681M$889M$936M
Gross Profit$403M$400M$225M$339M$393M
Gross Margin44%43%33%38%42%
EBITDA$409M$415M$198M$234M$372M
EBITDA Margin44%45%29%26%40%
EBIT Margin33%34%15%15%29%
Net Profit$273M$282M$91M$108M$240M
Net Margin30%30%13%12%26%
Net Debt-$295M---

Financial data powered by Morningstar, Inc.

Ypsomed Stock Performance

Ypsomed has current market cap of $6B, and enterprise value of $6B.

Market Cap Evolution


Ypsomed's stock price is $430.20.

Ypsomed share price decreased by 4.1% in the last 30 days, and by 20.1% in the last year.

Ypsomed has an EPS (earnings per share) of $21.47.

See more trading valuation data for Ypsomed
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$6B$6B-0.0%-4.1%21.8%-20.1%$21.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ypsomed Valuation Multiples

Ypsomed trades at 6.4x EV/Revenue multiple, and 14.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Ypsomed

EV / Revenue (LTM)


Ypsomed Financial Valuation Multiples

As of June 3, 2026, Ypsomed has market cap of $6B and EV of $6B.

Ypsomed has a P/E ratio of 20.7x.

LTMLast FY202320242025202620272028
EV/Revenue6.4x6.4x8.7x6.7x6.4x
EV/EBITDA14.6x14.3x30.1x25.5x16.0x
EV/EBIT19.4x19.0x58.6x44.1x22.0x
EV/Gross Profit14.8x14.9x26.4x17.6x15.1x
P/E20.7x20.0x62.1x52.2x23.6x
EV/FCF81.8x67.5x(137.7x)(44.7x)(105.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ypsomed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ypsomed Margins & Growth Rates

Ypsomed decreased revenue by 3% and EBITDA by 4% in the last fiscal year.

In the most recent fiscal year, Ypsomed reported gross margin of 43%, EBITDA margin of 45%, and net margin of 30%.

See estimated margins and future growth rates for Ypsomed

Ypsomed Margins

Last FY202420252026202720282029
Gross Margin43%38%42%46%
EBITDA Margin45%26%40%44%
EBIT Margin34%15%29%32%
Net Margin30%12%26%27%
FCF Margin9%(15%)(6%)(1%)

Ypsomed Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(3%)30%5%(3%)
Gross Profit Growth5%51%16%6%
EBITDA Growth(4%)18%59%8%
EBIT Growth(11%)33%100%6%
Net Profit Growth(18%)19%121%2%
FCF Growth(100%)208%(58%)(91%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Ypsomed Operational KPIs

Ypsomed's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.

Ypsomed's Rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ypsomed's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Ypsomed
LTMLast FY202320242025202620272028
Rule of 4044%41%---
Bessemer Rule of X44%38%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue7%7%15%12%8%
G&A Expenses to Revenue-5%5%5%5%
R&D Expenses to Revenue5%5%-5%5%
Opex to Revenue-9%18%23%13%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Ypsomed Competitors

Ypsomed competitors include Sysmex, Teleflex, Abbott India, Getinge, Sectra, Andon Health, Bausch + Lomb, Novanta, Asahi Intecc and Snibe.

Most Ypsomed public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sysmex1.7x1.7x7.2x8.6x
Teleflex4.0x3.7x13.0x13.1x
Abbott India7.7x7.6x24.6x27.7x
Getinge1.6x1.6x8.6x8.6x
Sectra16.6x16.4x64.0x62.6x
Andon Health25.2x-12.7x-
Bausch + Lomb2.0x1.9x11.4x10.7x
Novanta6.0x5.8x26.7x25.4x

This data is available for Pro users. Sign up to see all Ypsomed competitors and their valuation data.

Start Free Trial

Investments by Ypsomed

Ypsomed has invested in 1 company to date.

Latest investment by Ypsomed was on April 13th 2021. Ypsomed invested in CeQur Simplicity in their $115M Series C round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Ypsomed

CeQur Simplicity
Description
CeQur Simplicity is a Zug, Switzerland-based medical device company developing wearable bolus insulin delivery patches for type 2 diabetes management. The Simplicity platform delivers up to three days of automated dosing via button-activated patches, distributed through partnerships with pharmaceutical firms in Europe and the United States.
HQ CountrySwitzerland
HQ City
Lucerne
Deal Date13 Apr 2021
RoundSeries C
Raised$115M
InvestorsCredit Suisse Entrepreneur Capital; Endeavour Vision; Federated Kaufmann Fund; GMS Capital Partners; Kingdon Capital; Schroders; Tandem Diabetes Care; VI Partners; Ypsomed
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ypsomed investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ypsomed

When was Ypsomed founded?Ypsomed was founded in 2003.
Where is Ypsomed headquartered?Ypsomed is headquartered in Switzerland.
How many employees does Ypsomed have?As of today, Ypsomed has over 2K employees.
Who is the CEO of Ypsomed?Ypsomed's CEO is Simon Michel.
Is Ypsomed publicly listed?Yes, Ypsomed is a public company listed on SIX Swiss Exchange.
What is the stock symbol of Ypsomed?Ypsomed trades under YPSN ticker.
When did Ypsomed go public?Ypsomed went public in 2004.
Who are competitors of Ypsomed?Ypsomed main competitors include Sysmex, Teleflex, Abbott India, Getinge, Sectra, Andon Health, Bausch + Lomb, Novanta, Asahi Intecc, Snibe.
What is the current market cap of Ypsomed?Ypsomed's current market cap is $6B.
What is the current revenue of Ypsomed?Ypsomed's last 12 months revenue is $924M.
What is the current revenue growth of Ypsomed?Ypsomed revenue growth (NTM/LTM) is 0%.
What is the current EV/Revenue multiple of Ypsomed?Current revenue multiple of Ypsomed is 6.4x.
What is the current EBITDA of Ypsomed?Ypsomed's last 12 months EBITDA is $409M.
What is Ypsomed's EBITDA margin?Ypsomed's last 12 months EBITDA margin is 44%.
What is the current EV/EBITDA multiple of Ypsomed?Current EBITDA multiple of Ypsomed is 14.6x.
What is the current FCF of Ypsomed?Ypsomed's last 12 months FCF is $73M.
What is Ypsomed's FCF margin?Ypsomed's last 12 months FCF margin is 8%.
What is the current EV/FCF multiple of Ypsomed?Current FCF multiple of Ypsomed is 81.8x.
How many companies Ypsomed has acquired to date?Ypsomed hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Ypsomed has invested to date?As of June 2026, Ypsomed has invested in 1 company.
What was the last Ypsomed investment?On 13th April 2021 Ypsomed invested in CeQur Simplicity, participating in a $115M Series C round, alongside Credit Suisse Entrepreneur Capital, Endeavour Vision, Federated Kaufmann Fund, GMS Capital Partners, Kingdon Capital, Schroders, Tandem Diabetes Care, and VI Partners.
In what companies Ypsomed invested in?Ypsomed invested in CeQur Simplicity.

See public comps similar to Ypsomed

Lists including Ypsomed

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial